Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review

Topical use of immune response modifiers, such as imiquimod, has increased in dermatology. Although its topical use is well tolerated, it may be associated with exacerbations of generalized cutaneous inflammatory diseases, possibly through the systemic circulation of pro-inflammatory cytokines. This report describes a case of development of pityriasis rubra pilaris, a rare erythematous-papulosquamous dermatosis, in a woman aged 60 years during treatment with imiquimod 5% cream for actinic keratosis. It evolved with erythrodermic conditions and palmoplantar keratoderma, presenting progressive clinical resolution after the introduction of methotrexate. The authors emphasize the importance of recognizing possible systemic reactions associated with the topical use of imiquimod.     

The clinics of HHV‐6 infection in COVID‐19 pandemic: Pityriasis rosea and Kawasaki disease

A new type of coronavirus family (SARS‐CoV‐2), which can be found in humans and animals, with many varieties and clinical symptoms, was first seen in Wuhan, China in late 2019, under the name novel Coronavirus Disease 2019 (COVID‐19). In the literature, cutaneous symptoms related to the disease are generally emphasized. However, it is not yet known whether this new SARS‐CoV‐2 virus, which has entered our lives, plays a role in the etiopathogenesis of dermatological diseases. The patients who were admitted to the dermatology outpatient clinic between 1 April and 15 May 2019, and on 1 April and 15 May 2020 were retrospectively analyzed by searching the hospital automation system and patient files. The reason for the same months to be included in the study was to exclude seasonal effects on the diseases. After pandemic, the number of patients with Pityriasis rosea and Kawasaki disease increased significantly in patients who applied to the dermatology outpatient clinic. Our study is the first study showing Pityriasis rosea increase during the pandemic period. We think that this increase is related to HHV‐6 reactivation. Herein, we wanted to draw attention to two diseases in which Human Herpes 6 (HHV‐6) was accused in etiopathogenesis: Kawasaki disease and Pityriasis rosea.     

儿童白色糠疹与血微量元素的相关性探讨

目的：探讨儿童白色糠疹与血微量元素的相关性。方法：用比色法及原子吸收法测定208例白色糠疹患儿血清微量元素情况，并以747例健康儿童作为对照。结果：白色糠疹患儿缺锌、缺钙者比例明显高于健康对照组，差异有统计学意义（X^2值分别为4．45、6．38，P值均〈0．05）；白色糠疹患儿血清中锌、钙水平明显低于健康对照组，差异有统计学意义（t值分别为2．29、3．59，P值均〈0．05），而镁、铁、铜、铅及25羟基维生素D水平与健康对照组相比，差异均无统计学意义（P值均〉0．05）。结论：白色糠疹患儿体内存在缺锌、缺钙情况，临床上应注意早期干预、早期治疗。     

玫瑰疹病毒属与玫瑰糠疹发病的相关性研究现况

玫瑰糠疹是一种病因尚未明确的炎症性、自限性红斑鳞屑性皮肤病，至今病因尚未明确。近年来，关于玫瑰糠疹与玫瑰疹病毒属人疱疹病毒6、7型的研究较为深入，本文对相关文献进行了综述。     

盐酸伐昔洛韦联合复方甘草酸苷治疗玫瑰糠疹的临床观察

目的:观察盐酸伐昔洛韦联合复方甘草酸苷治疗玫瑰糠疹的临床疗效和安全性。方法:将107例玫瑰糠疹患者随机分为对照组(志愿者,n=37)、观察组(n=35)和研究组(n=35)。对照组患者不给予用药治疗,等待自愈;观察组患者给予复方甘草酸苷3片,口服,每日3次;研究组患者在观察组治疗的基础上给予盐酸伐昔洛韦250 mg,口服,每日3次。3组患者均观察2周。观察3组患者未用药或用药1周、2周后疗效,并记录不良反应发生情况。结果:治疗1周后,研究组患者总有效率>观察组>对照组,3组比较差异有统计学意义(P<0.05);治疗2周后,研究组与观察组患者总有效率均显著高于对照组,差异均有统计学意义(P<0.05),但研究组与观察组比较差异无统计学意义(P>0.05)。3组患者观察期间均未见明显不良反应发生。结论:盐酸伐昔洛韦联合复方甘草酸苷治疗玫瑰糠疹较单用复方甘草酸苷或未用药物疗效较好、起效较快,安全性相似。     

复方青黛胶囊配合窄谱中波紫外线治疗玫瑰糠疹的临床观察

目的探讨复方青黛胶囊配合窄谱中波紫外线治疗玫瑰糠疹的临床疗效。方法选取2011年1月至2012年12月在我院治疗的玫瑰糠疹患者82例,按照随机数字表法随机分为治疗组40例,对照组42例。治疗组采用复方青黛胶囊配合窄谱中波紫外线治疗;对照组采用窄谱中波紫外线治疗。结果治疗组总有效率(90.5%)明显高于对照组(67.5%),两组比较差异具有统计学意义(P<0.05);对照组不良反应发生率(17.5%)与治疗组(12.5%)比较,差异无统计学意义(P>0.05)。结论复方青黛胶囊配合窄谱中波紫外线治疗玫瑰糠疹临床疗效明显且不良反应较轻,值得推广。     

蔷薇红景天乙酸乙酯部位化学成分的研究

提取、分离并鉴定新疆产蔷薇红景天根茎中乙酸乙酯部位的化学成分.方法采用硅胶等色谱技术进行分离纯化,通过化学反应和光谱分析方法(MS、1HNMR、13CNMR及二维核磁共振谱等)进行结构鉴定.结果从蔷薇红景天根茎中分离得到了5个单体化合物,分别鉴定为酪醇、山柰酚、大花红景天素、β-谷甾醇和胡萝卜苷.结论大花红景天素是从蔷...     

清金畅肺饮治疗慢性阻塞性肺疾病急性加重期的临床观察

目的观察清金畅肺饮治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效。方法采用随机对照方法将83例慢性阻塞性肺疾病患者随机分为治疗组42例和对照组41例,治疗组西医常规治疗上加服中药清金畅肺饮,对照组西医常规治疗,观察两组治疗前后临床症状、体征及实验室相关指标的变化。结果治疗组与对照组均可改善临床症状、体征,降低PaCO2、CRP,治疗前后比较差异有统计学意义(P<0.05,P<0.01),治疗后两组间比较差异亦有统计学意义(P<0.05)。两组均升高PaO2(P<0.01~0.05),两组间比较差异无统计学意义(P>0.05),均升高FVC、FEV1%,治疗组治疗前后比较差异有统计学意义(P<0.01),对照组治疗前后比较差异无统计学意义(P>0.05),治疗后两组间比较差异有统计学意义(P<0.05)。结论清金畅肺饮治疗COPD临床有效,其作用机制可能与改善气道炎症以达到改善气流受限有关。